Bitopertin治疗精神分裂症阴性症状:III期FlashLyte与DayLyte研究结果
两项III期随机双盲安慰剂对照研究(DayLyte和FlashLyte)评估辅助bitopertin对稳定期精神分裂症持续 predominant 阴性症状的疗效与安全性。共纳入605例和594例意向治疗患者,24周时所有治疗组阴性症状因子分均改善,但bitopertin各剂量与安慰剂无统计学显著差异,药物耐受良好。
要点
- 辅助bitopertin 5mg、10mg(DayLyte)及10mg、20mg(FlashLyte)在24周时对阴性症状因子分的改善均未显著优于安慰剂。
- Bitopertin在所有测试剂量下耐受性良好。
- 研究未提供bitopertin治疗精神分裂症持续 predominant 阴性症状优于安慰剂的证据。
核心结论
- 在精神分裂症持续 predominant 阴性症状患者中,辅助bitopertin在所测试的任何剂量下均未显示优于安慰剂的疗效。
研究设计与样本
- 三项III期、多中心、随机、24周、双盲、平行组、安慰剂对照研究(SunLyte、DayLyte、FlashLyte)评估辅助bitopertin的疗效与安全性,其中SunLyte因预设无效标准被宣布无效。
- DayLyte和FlashLyte的意向治疗人群分别包括605例和594例患者,随机1:1:1接受bitopertin(DayLyte 5mg和10mg;FlashLyte 10mg和20mg)或安慰剂每日一次,共24周。
主要发现
- 第24周时,所有治疗组阳性与阴性症状量表阴性症状因子分较基线均有改善,但bitopertin与安慰剂之间无统计学显著差异,所有其他终点亦无显著差异。
- Bitopertin耐受性良好。
关键数值与推荐
- 关键纳入标准:年龄≥18岁、DSM-IV-TR精神分裂症诊断、阳性与阴性症状量表14项阴性症状与思维紊乱因子总分≥40、抗精神病药治疗未改变且临床稳定。
- 主要疗效终点为第24周阳性与阴性症状量表阴性症状因子分较基线的平均变化。
临床怎么用
- 不推荐使用bitopertin治疗精神分裂症持续 predominant 阴性症状,因其在所测试剂量下未显示优于安慰剂的疗效。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is currently no standard of care for treatment of negative symptoms of schizophrenia, although some previous results with glutamatergic agonists have been promising. METHODS: Three (SunLyte [WN25308], DayLyte [WN25309], and FlashLyte [NN25310]) phase III, multicenter, randomized, 24-week, double-blind, parallel-group, placebo-controlled studies evaluated the efficacy and safety of adjunctive bitopertin in stable patients with persistent predominant negative symptoms of schizophrenia treated with antipsychotics. SunLyte met the prespecified criteria for lack of efficacy and was declared futile. Key inclusion criteria were age ≥18 years, DSM-IV-TR diagnosis of schizophrenia, score ≥40 on the sum of the 14 Positive and Negative Syndrome Scale negative symptoms and disorganized thought factors, unaltered antipsychotic treatment, and clinical stability. Following a 4-week prospective stabilization period, patients were randomly assigned 1:1:1 to bitopertin (5 mg and 10 mg [DayLyte] and 10 mg and 20 mg [FlashLyte]) or placebo once daily for 24 weeks. The primary efficacy end point was mean change from baseline in Positive and Negative Syndrome Scale negative symptom factor score at week 24. RESULTS: The intent-to-treat population in DayLyte and FlashLyte included 605 and 594 patients, respectively. At week 24, mean change from baseline showed improvement in all treatment arms but no statistically significant separation from placebo in Positive and Negative Syndrome Scale negative symptom factor score and all other end points. Bitopertin was well tolerated. CONCLUSIONS: These studies provide no evidence for superior efficacy of adjunctive bitopertin in any of the doses tested over placebo in patients with persistent predominant negative symptoms of schizophrenia.
引用
- Bugarski-Kirola D, Blaettler T, Arango C, et al. Bitopertin in Negative Symptoms of Schizophrenia-Results From the Phase III FlashLyte and DayLyte Studies. Biol Psychiatry. 2016. PMID: 28117049. doi:10.1016/j.biopsych.2016.11.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。